Phase 1 Study on Safety, Pharmacokinetics, and Pharmacodynamics of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis Patients

The primary objective of this study is to evaluate the **safety**, pharmacokinetics, and pharmacodynamics of Siplizumab in newly diagnosed adult patients with **Amyotrophic Lateral Sclerosis** (ALS) over a 52-week period. This is crucial for determining the potential therapeutic benefits and risks associated with Siplizumab in the treatment of ALS, a progressive neurodegenerative disease characterized by the degeneration of motor neurons, leading to muscle weakness and atrophy. Understanding the safety profile and biological effects of Siplizumab will inform future clinical applications and therapeutic strategies for ALS management.

The clinical trial involves participants diagnosed with **Amyotrophic Lateral Sclerosis**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been detailed in the available data.

The clinical trial is a **Phase 3** study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of Siplizumab in adult patients newly diagnosed with **Amyotrophic Lateral Sclerosis** (ALS). The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is set to commence recruitment on December 1, 2023, and is expected to conclude by December 31, 2026, spanning a total duration of 52 weeks for each participant.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, there will be regular follow-up visits to monitor the participants' health, collect data on the drug's effects, and ensure adherence to the study protocol. These visits are crucial for evaluating the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment.

The expected length of participant involvement is approximately one year, contingent upon adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines to ensure the safety and well-being of all participants throughout the study duration.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in the study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on December 1, 2023, with an estimated completion date of December 31, 2026. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy outcomes.